Segment Information - Schedule of Financial Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Net sales	$ 5,935	$ 2,660
Gross profit	1,909	1,418
Direct expenses	36,568	24,616
Segment contribution	(34,659)	(23,198)
Indirect expenses	6,955	21,197
Loss from operations	(41,614)	(44,395)
Components of other
Change in fair value of contingent consideration liability	4,849	20,656
Change in fair value of contingent stock consideration	1,565
Cell Therapy
Segment Reporting Information [Line Items]
Direct expenses	21,213	16,287
Segment contribution	(21,213)	(16,287)
Biobanking
Segment Reporting Information [Line Items]
Net sales	1,283	1,264
Gross profit	335	540
Direct expenses	626	252
Segment contribution	(291)	288
Degenerative Disease
Segment Reporting Information [Line Items]
Net sales	4,652	1,396
Gross profit	1,574	878
Direct expenses	1,459	2,014
Segment contribution	115	(1,136)
Other
Segment Reporting Information [Line Items]
Direct expenses	13,270	6,063
Segment contribution	(13,270)	(6,063)
Indirect expenses	6,955	21,197
Components of other
Change in fair value of contingent consideration liability	4,849	20,656
Change in fair value of contingent stock consideration	1,565
Amortization	541	541
Total other	$ 6,955	$ 21,197